EpiScreen® 2.0: Smarter Immunogenicity Testing - Abzena

EpiScreen® 2.0: Smarter Immunogenicity Testing

Avoid issues later in the drug development process, start smart.

Download Info Sheet

Accurate assessment of immunogenicity can make or break the success of protein therapeutics. Traditional assays often lack the sensitivity, and specificity required. Next-generation EpiScreen® 2.0 is Abzena’s innovative answer to these challenges, utilizing flow cytometry technology for precise, multi-dimensional immunogenicity assays.

EpiScreen® 2.0 Info Sheet: Immunogenicity testing evolved

Our enhanced bioassay platform EpiScreen® 2.0, is a comprehensive suite of assays that predict and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics.

Our next-generation platform provides a better immunogenic assessment. An assessment that is highly sensitive, multi-parametric, and data-rich, which ultimately improves candidate selection and de-risks early-phase development for our customers.

Download
EpiScreen® 2.0: Smarter Immunogenicity Testing - Abzena

Optimizing your immunogenicity assays

To avoid issues later in the drug development process, it is important to start smart with more data-rich assays. We have recently introduced our next-generation EpiScreen® 2.0 technology to elevate the immunogenicity evaluation of protein therapeutics. EpiScreen® 2.0 is high sensitivity and a multi-dimensional, data-rich platform that streamlines the candidate selection helping de-risk the drug development process.

Immunogenicity Assays

Move your drug development program forward, at less risk, with EpiScreen® 2.0.

EpiScreen® 2.0 delivers all the required sensitivity, plus detailed data on specificity and mechanism of action, without the need for radioactive markers.

Contact Us

Related Content

EpiScreen® 2.0 DC:T Cell Assay

Assessing antibody immunogenicity and the 'adjuvant effect' of different product formulations on immunogenicity.

Learn More

EpiScreen® 2.0 MAPPs: MHC Class II Associated Peptide Proteomics

Identifying MHC Class II bound peptides processed and presented by dendritic cells (DCs) from therapeutic proteins/mAbs.

Learn More

EpiScreen® 2.0 T Cell Epitope Mapping

Identifying CD4+ T cell epitopes within protein sequences in order to design deimmunized variants.

Learn More

EpiScreen® 2.0 Time Course T Cell Assay

These assays have been used extensively as a standard for preclinical immunogenicity testing.

Learn More

Episcreen® 2.0 Cytokine Screen™

We can assess a biopharmaceutical product's immune modulating potential by assessing its ability to stimulate cytokine production.

Learn More

EpiScreen® 2.0: Immunogenicity Testing Evolved

Learn More

Featured News & Insights

Blog

Blog: Immunogenicity Assessments – Frequently Asked Questions

Read More

News

Abzena Launches EpiScreen® 2.0 Immunogenicity Platform

Read More

Articles

Abzena Recognized as Top CDMO in 2024 by Pharma Tech Outlook

Read More